Education
About Us
Working with TipRanks
Follow Us
Zydus Lifesciences Limited (IN:ZYDUSLIFE)
:ZYDUSLIFE
RESEARCH TOOLSreports
Total Valuation
Zydus Lifesciences Limited has a market cap or net worth of ₹984.85B. The enterprise value is ₹506.31B.
Market Cap₹984.85B
Enterprise Value₹506.31B
Share Statistics
Zydus Lifesciences Limited has 1,006,234,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,006,234,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zydus Lifesciences Limited’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 14.63%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.13
Return on Invested Capital (ROIC)14.63%
Return on Capital Employed (ROCE)0.19
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.67
Inventory Turnover3.09
Valuation Ratios
The current PE Ratio of Zydus Lifesciences Limited is 26.21. Zydus Lifesciences Limited’s PEG ratio is 2.72.
PE Ratio26.21
PS Ratio0.00
PB Ratio2.85
Price to Fair Value5.10
Price to FCF30.11
Price to Operating Cash Flow18.57
PEG Ratio2.72
Income Statement
In the last 12 months, Zydus Lifesciences Limited had revenue of 195.47B and earned 38.59B in profits. Earnings per share was 38.14.
Revenue195.47B
Gross Profit89.25B
Operating Income45.40B
Pretax Income48.09B
Net Income38.59B
EBITDA56.22B
Earnings Per Share (EPS)38.14
Cash Flow
In the last 12 months, operating cash flow was 11.18B and capital expenditures 0.00, giving a free cash flow of 11.18B billion.
Operating Cash Flow11.18B
Free Cash Flow11.18B
Free Cash Flow per Share11.11
Dividends & Yields
Zydus Lifesciences Limited pays an annual dividend of ₹3, resulting in a dividend yield of 0.31%
Dividend Per Share₹3
Dividend Yield0.31%
Payout Ratio6.78%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-11.52%
50-Day Moving Average895.22
200-Day Moving Average969.85
Relative Strength Index (RSI)74.15
Average Volume (3m)37.82K
Important Dates
Zydus Lifesciences Limited upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 20, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend DateJul 25, 2025
Financial Position
Zydus Lifesciences Limited as a current ratio of 2.14, with Debt / Equity ratio of 6.82%
Current Ratio2.14
Quick Ratio1.49
Debt to Market Cap<0.01
Net Debt to EBITDA0.07
Interest Coverage Ratio92.27
Taxes
In the past 12 months, Zydus Lifesciences Limited has paid 9.78B in taxes.
Income Tax9.78B
Effective Tax Rate0.20
Enterprise Valuation
Zydus Lifesciences Limited EV to EBITDA ratio is 18.06, with an EV/FCF ratio of 43.75.
EV to Sales5.20
EV to EBITDA18.06
EV to Free Cash Flow43.75
EV to Operating Cash Flow31.46
Balance Sheet
Zydus Lifesciences Limited has ₹13.58B in cash and marketable securities with ₹8.04B in debt, giving a net cash position of -₹5.53B billion.
Cash & Marketable Securities₹13.58B
Total Debt₹8.04B
Net Cash-₹5.53B
Net Cash Per Share-₹5.50
Tangible Book Value Per Share₹140.57
Margins
Gross margin is 62.61%, with operating margin of 23.22%, and net profit margin of 19.74%.
Gross Margin62.61%
Operating Margin23.22%
Pretax Margin24.60%
Net Profit Margin19.74%
EBITDA Margin28.76%
EBIT Margin24.83%
Analyst Forecast
The average price target for Zydus Lifesciences Limited is ₹1,088.33, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹1,088.33
Price Target Upside23.29% Upside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―